Argentina Antifungal Drugs Market Size & Outlook
Argentina antifungal drugs market, 2018-2030 (US$M)
Related Markets
Argentina antifungal drugs market highlights
- The Argentina antifungal drugs market generated a revenue of USD 93.9 million in 2023 and is expected to reach USD 126.8 million by 2030.
- The Argentina market is expected to grow at a CAGR of 4.4% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 93.9 million |
| Market revenue in 2030 | USD 126.8 million |
| Growth rate | 4.4% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Argentina accounted for 0.6% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 262.6 million by 2030.
Azoles was the largest segment with a revenue share of 47.5% in 2023. Horizon Databook has segmented the Argentina antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
The large number of antifungal manufacturing sites in the country is a key driver of the country’s market. Collaborations between companies are further propelling market growth.
Key players are focusing on development of new antifungal products and approval of such products, which is also boosting market growth. For instance, in September 2018, BIOTOSCANA INVESTMENTS S.A. received approval for CRESEMBA (isavuconazole) in Argentina.
In May 2020, Fresenius Kabi launched a generic version of Mycamine (echinocandin antifungal), Micafungin for Injection. The National Administration of Drugs, Foods, and Medical Devices (ANMAT) is the regulatory authority for drugs and medicinal products in Argentina.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Argentina antifungal drugs market size, by drug class, 2018-2030 (US$M)
Argentina Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
